Pharmakologische Grundlagen der Prostaglandin-Therapie

Zusammenfassung

Vasodilatierende Prostaglandine werden zur Therapie fortgeschrittener Stadien der peripheren arteriellen Verschlußkrankheit und der Thrombangiitis obliterans eingesetzt. Der klinische Nutzen liegt vor allem in der therapeutischen Anwendung in Fällen, wo chirurgische Maßnahmen nicht angezeigt bzw. erfolglos geblieben sind. Eine Reihe von klinischen Studien belegt die klinische Wirksamkeit der systemischen Anwendung von Prostaglandin E₁ und lloprost. Die pharmakologischen Wirkungen dieser Substanzen betreffen nicht nur den Vasotonus, sondern auch Zellen des strömenden Blutes sowie das Fibrinolyseund Gerinnungssystem. Neuere experimentelle Befunde weisen auf eine antiatherosklerotische Wirkung der Prostaglandine hin.

Schlüsselwörter

Prostaglandine - Vasotonus - Thrombozyten - neutrophile Granulozyten - Fibrinolyse - Atherosklerose

• Literatur

• 1 Bertelé V, Mussoni L, del Rosso G, Pintucci G, Carriero MR, Merati MG, Libretto A, de Gaetano G. Defective fibrinolytic response in atherosclerotic patients effect of iloprost and its possible mechanism of action. Thromb Haemostas 1988; 60: 141-4.
• 2 Braun M, Sarbia M, Kienbaum P, Hohlfeld Th, Weber A, Schrör K. Antiatherosclerotic properties of oral cicaprost in hypercholesterolemic rabbits. Agents and Actions 1992; (Suppl) 37: 282-8.
• 3 Braun M, Schrör K. Prostaglandin D₂ relaxes bovine coronary arteries by endothelium-dependent nitric oxide-mediated cGMP formation. Circ Res 1992; 71: 1305-13.
• 4 Chopra J, Webster PO. PGE₁ inhibits neutrophil adherence and neutrophil-mediated injury to cultured endothelial cells. Am Rev Respir Dis 1988; 138: 915-20.
• 5 Coleman RA, Kennedy I, Humphrey PPA, Bunce K, Lumley P. Prostanoids and their receptors. In: Emmett J. (ed). Comprehensive Medicinal Chemistry. Vol. 3. Membranes and Receptors. Oxford: Pergamon Press; 1990: 643-714.
• 6 Crutchely DJ, Conanan LB, Maynard JR. Stimulation of fibrinolytic activity in human skin fibroblasts by prostaglandin E₁, E₂, and I₂ . J Pharmacol Exp Ther 1982; 222: 544-9.
• 7 Crutchely DJ, Hirsh MJ. The stable prostacyclin analog, iloprost, and prostaglandin E₁ inhibit monocyte procoagulant activity in vitro. Blood 1991; 78: 382-6.
• 8 Darius H, Kopp H, Mulfinger A, Spielberger M, Todt M, Schuster CJ, Meyer J. Pilot study of the effects of taprostene (CG 4203) in patients with advanced peripheral arterial disease. Prog Clin Res 1989; 301: 417-21.
• 9 Diamond J, Vegesna RV. Elevation of cyclic AMP by prostaglandins is accompanied by relaxation of bovine coronary arteries and contraction of rabbit aortic rings. Eur J Pharmacol 1986; 128: 25-31.
• 10 European working group on critical leg ischemia. Second european consensus document on chronic critical leg ischemia. Circulation 1991; (Suppl) 84: IV1-IV26.
• 11 Fisher CA, Kappa JR, Sinha AK, Cottrell ED, Reiser HJ, Addonizio VP. Comparison of equimolar concentrations of iloprost, prostacyclin and prostaglandin E₁ on human platelet function. J Lab Clin Med 1987; 109: 184-90.
• 12 Fitscha P, Kaliman J, Sinzinger H. Platelet sensitivity to antiaggregatory prostaglandins (PGE₁, D₂, I₂) in patients with peripheral vascular disease. Am J Hematol 1985; 19: 13-20.
• 13 Fredrich M, Müller B. Prostacyclin and atherosclerosis. In: Rubanyi GM, Vane J. (eds). Prostacyclin: New Perspectives for Basic Research and Novel Therapeutic Indications. Amsterdam: Elsevier; 1992: 169-80.
• 14 Grabitz K, Freye E, Prior R, Schrör K, Sandmann W. Does prostaglandin E₁ and Superoxide dismutase prevent ischaemic spinal cord injury after thoracic aortic crossclamping?. Eur J Vase Surg 1990; 04: 19-24.
• 15 Grant SM, Goa KL. Iloprost. A review of its pharmacodynamic properties and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporal circulation procedures. Drugs 1992; 43: 888-924.
• 16 Gryglewski R, Salvemini D. Modulation of polymorphonuclear function by prostaglandins and nitric oxide. In: Rubanyi GM, Vane J. (eds). Prostacyclin: New Perspectives for Basic Research and Novel Therapeutic Indications. Amsterdam: Elsevier; 1992: 59-92.
• 17 Hajjar DP, Pomerantz KB. Eicosanoids and their role in atherosclerosis. Arch Mai Coeur Vaiss 1989; 89: 21-6.
• 18 Hecker G, Ney P, Schrör K. Cytotoxic enzyme release and oxygen centered radical formation in human neutrophils are selectively inhibited by E-type prostaglandins but not by PGI₂ . Naunyn-Schmiedeberg’s Arch Pharmacol 1990; 341: 308-15.
• 19 Heidrich H, Breddin HK, Rudofsky G, Scheffler P. Kardiopulmonale Wirkungen von PGE₁. Aspekte zur Arzneimittelsicherheit. Med Klin 1992; 87: 123-30.
• 20 Hildebrand M, Krause W, Oberender HA, Zurdel-Dillinger S, Jünger M, Bodenburg H. Pharmacokinetics of iloprost in patients with severe peripheral arterial occlusive disease. Eicosanoids 1990; 03: 145-8.
• 21 Ito S, Hashimoto H, Negishi M, Suzuki M, Koyano H, Noyori R, Ichikawa A. Identification of the prostacyclin receptor by use of [15-³H₁]19-(3-azidophenyl)-20-norisocarbacyclin, an irreversible specific photoaffinity probe. J Biol Chem 1992; 267: 20326-30.
• 22 Jaschonek K, Faul C, Schmidt H, Renn W. Desensitization of platelets to iloprost. Loss of specific binding sites and heterologous desensitization of adenylate cyclase. Eur J Pharmacol 1988; 147: 187-96.
• 23 MacIntyre DE, Bushfield M, MacMillan LJ, Moffat KJ, Murdoch FA, Thomson A, Rossi AG, McNicol A. Receptors and receptor mechanisms of endogenous platelet stimulatory and inhibitory mediators. Agents Actions 1986; (Suppl) 20: 45-62.
• 24 Murata T, Murai T, Kanai T, Ogaki Y, Sanai K, Kanda H, Sato S, Kajikawa N, Umetsu T, Matsuura H. General pharmacology of beraprost. 2nd communication: effect on the autonomic cardiovascular and gastrointestinal systems and other effects. Arzneimittelforschung 1989; 39: 867-76.
• 25 Musial J, Wilczynska M, Sladek K, Cierniewski CS, Nizankowski R, Szczeklik A. Fibrinolytic activity of prostacyclin and iloprost in patients with peripheral arterial disease. Prostaglandins 1986; 31: 61-70.
• 26 Ney P, Braun M, Szymanski Ch, Bruch L, Schrör K. Antiplatelet, antineutrophil and vasodilating properties of 13,14-dihydro- PGE₁ (PGE₀) an in vivo metabolite of PGE₁ in man. Eicosanoids 1991; 04: 177-84.
• 27 Nicolini FA, Mehta P, Lawson D, Mehta JL. Reduction in human neutrophil chemotaxis by the prostacyclin analogue iloprost. Thromb Res 1990; 59: 669-74.
• 28 Peskar BA, Hesse WH, Rogatti W, Diehm C, Rudofsky G, Schweer H, Seyberth HW. Formation of 13,14-dihydro-prostaglandin E₁ during intravenous infusion of prostaglandin E₁. in patients with peripheral arterial occlusive disease. Prostaglandins 1991; 41: 225-8.
• 29 Pietila K, Moilanen T, Nikkari T. Prostaglandins enhance the synthesis of glycosaminoglycans and inhibit the growth of rabbit aorta smooth muscle cells in culture. Artery 1980; 07: 509-18.
• 30 Riva CM, Morganroth ML, Marks RM, Todd RF, Ward PA. et al. Iloprost inhibits activated human neutrophil (PMN) adherence to endothelial cells via increased cyclic AMP. Clin Res 1989; 37: 949A.
• 31 Ross R. The pathogenesis of atherosclerosis an update. N Engl J Med 1986; 314: 488-500.
• 32 Rossi AG, O’Flaherty JT. Prostaglandin binding sites in human polymorphonuclear neutrophils. Prostaglandins 1989; 37: 641-53.
• 33 Scheffler P, de-la Hamette D, Leipnitz G, Gross J. Effects of intravenous PGE₁ on blood flow and microcirculation: a doubleblind, placebo-controlled study in patients with critical limb ischemia. In: Diehm C, Sinzinger H, Rogatti W. (eds). Prostaglandin E₁ . Berlin: Springer; 1992: 91-100.
• 34 Scheffler P, de-la Hamette D, Pindur G, Gross J, Darbringhaus S. Ein neues orales Prostaglandin-E₁ Derivat (OP 1206): Nachweis der Wirkung auf die Makround Mikrozirkulation. VASA 1991; (Suppl) 32: 386-91.
• 35 Schrör K. Cytoprotective properties of prostacyclin. In: Rubanyi GM, Vane J. (eds). Prostacyclin: New Perspectives for Basic Research and Novel Therapeutic Indications. Amsterdam: Elsevier; 1992: 157-68.
• 36 Schrör K, Hecker G. Different effects of E-and I-type prostaglandins on human platelet and polymorphonuclear cell function. In: Sinzinger H, Rogatti W. (eds). Prostaglandin E₁ in Atherosclerosis. Berlin: Springer; 1986: 22-31.
• 37 Schrör K, Thiemermann C, Ney P. Protection of the ischemic myocardium from reperfusion injury by prostaglandin E₁: Inhibition of ischemia induced neutrophil activation. Naunyn Schmiedeberg’s Arch Pharmacol 1988; 338: 268-74.
• 38 Schwartz SM, Reidy MA. Common mechanisms of proliferation of smooth muscle in atherosclerosis and hypertension. Human Pathol 1987; 18: 240-7.
• 39 Seiler S, Brassard CL, Arnold AJ, Meanwell NA, Fleming JS, Keely SL. Octimibate inhibition of platelet aggregation: Stimulation of adenylate cyclase through prostacyclin receptor activation. J Pharmacol Exp Ther 1990; 255: 1021-6.
• 40 Siess W. Molecular mechanisms of platelet activation. Pharmacol Rev 1989; 69: 58-178.
• 41 Sinzinger H. Inhibition of mitotic and proliferative activity of smooth muscle cells by prostaglandin E₁ . In: Sinzinger H, Rogatti W. (eds). Prostaglandin E_x in Atherosclerosis. Berlin: Springer; 1986: 39-48.
• 42 Sinzinger H, Fitscha P. Influence of PGE₁ on in-vivo accumulation of radiolabelled platelets and LDL on human arteries. VASA 1987; (Suppl) 17: 5-10.
• 43 Southgate K, Newby AC. Serum-induced proliferation of rabbit aortic smooth muscle cells from the contractile state is inhibited by 8-Br-cAMP but not 8-Br-cGMP. Atherosclerosis 1990; 82: 113-23.
• 44 Stamler JB, Vaughan DE, Loscalzo J. Synergistic disaggregation of platelets by tissuetype plasminogen activator, prostaglandin E₁ and nitroglycerin. Circ Res 1989; 65: 796-804.
• 45 Stürzebecher S, Haberey M, Müller B, Schillinger E, Schröder G, Skuballa W, Stock G, Vorbrüggen H, Witt W. Pharmacological profile of a novel carbacyclin derivative with high metabolic stability and oral activity in the rat. Prostaglandins 1986; 31: 95-109.
• 46 Terres W, Beythien C, Küpper W, Bleifeld W. Effects of aspirin and prostaglandin E₁. on in vitro thrombolysis with urokinase. Evidence for a possible role of inhibiting platelet activity in thrombolysis. Circulation 1989; 79: 1309-14.
• 47 Tertov VV, Orekhov AN, Smirnov VN. Agents that increase cellular cAMP inhibit proliferative activity and decrease lipid content in cells cultured form atherosclerotic human aorta. Artery 1986; 13: 365-72.
• 48 Tilsner V. Aktivierung der endogenen Fibrinolyse durch Prostaglandin E₁ . In: Heidrich H, Böhme H, Rogatti W. (Hrsg). Prostaglandin E₁ Wirkungen und therapeutische Wirksamkeit. Berlin: Springer; 1988: 76-82.
• 49 Torsello G, Schrör K, Szabo Z, Kutkuhn B, Strobach H, Godehardt E, Sandmann W. Effects of prostaglandin E₁ (PGE₁) on experimental renal ischemia. Eur J Vase Surg 1989; 03: 5-13.
• 50 Town M-H, Schillinger E, Speckenbach A, Prior G. Identification and characterization of a prostacyclin-like receptor in bovine coronary arteries using a specific and stable prostacyclin analogue, iloprost, as radioactive ligand. Prostaglandins 1982; 24: 61-72.
• 51 Vaughan DE, Plavon SR, Schafer AI, Loscalzo J. PGE₁ accelerated thrombolysis by tissue plasminogen activator. Blood 1989; 73: 1213-7.
• 52 Virgolini I, Fitscha P, Sinzinger H, Barth H. Effects of taprostene, a stable prostacyclin analogue, on haemodynamics, platelet function and arachidonate metabolism in healthy volunteers. Eur J Clin Pharmacol 1990; 38: 247-50.
• 53 Watson S, Abbott A. Receptor Nomenclature Supplement. Trends Pharmacol Sci 1990; (Suppl) 11: 23.
• 54 Weissmann G, Smolen JE, Korchak H. Prostaglandins and inflammation: Receptor/cyclase coupling as an explanation why PGE’s and PGI₂ inhibit function of inflammatory cells. Adv Prostaglandin Thromboxane Res 1980; 08: 1637-53.
• 55 Willis AL, Smith DL. Therapeutic impact of eicosanoids in atherosclerotic disease. Eicosanoids 1989; 02: 69-99.